This is a preview of subscription content, log in via an institution to check access.
Notes
Global Alliance for Vaccines and Immunizations
The study was funded by Glaxo SmithKline Biologicals S.A.
Reference
Sauboin C, et al. Comparing the Estimated Public Health Impact and Cost-Effectiveness of Phid-Cv and Pcv-13 in the Routine Immunisation Programme in Gavi-Eligible Countries (Sub-Saharan Africa and Asia/Oceania): a Modelling Study. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PIN34, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85979?pdfid=56806
Rights and permissions
About this article
Cite this article
Assessing cost effectiveness of pneumococcal conjugate vaccines. PharmacoEcon Outcomes News 817, 8 (2018). https://doi.org/10.1007/s40274-018-5465-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5465-2